Trastuzumab biosimilar is under clinical development by Tanvex BioPharma and currently in Pre-Registration for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer). According to GlobalData, Pre-Registration drugs for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Trastuzumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trastuzumab biosimilar overview
Trastuzumab biosimilar (TX-05) is under development for the treatment of HER2 positive early breast cancer. It is administered through intravenous route. The drug candidate acts by targeting cells expressing tyrosine kinase type cell surface receptor HER2.
Tanvex BioPharma overview
Tanvex BioPharma is a clinical-stage biopharmaceutical company that manufactures, researches, develops, and commercializes pharmaceutical and biopharmaceutical products. Its pipeline products include TX01, TX05, TX16 and TX17, among others. Its products are used for the treatment of neutropenia, metastatic colorectal cancer, breast cancer, and rheumatoid arthritis, among others. Tanvex BioPharma also develops biologic and biosimilar drugs and commercially viable cell culture processes for mammalian and microbial systems providing cell banking process definition, scale-up, and generation of toxicology materials, among others. The company’s services such as drug substance and products manufacturing, warehousing, sales and distribution services. It has operations in Taiwan and the US. Tanvex BioPharma is headquartered in Grand Cayman, Cayman Islands.
For a complete picture of Trastuzumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
